Literature DB >> 11377705

Polymorphism of CC chemokine receptors CCR2 and CCR5 in Crohn's disease.

H Herfarth1, B Pollok-Kopp, M Göke, A Press, M Oppermann.   

Abstract

Crohn's disease (CD) is a chronic inflammatory disease of the intestine that is characterized by mononuclear cell infiltration and a predominant Th1 lymphocyte response. We tested the hypothesis that CC chemokine receptors CCR2 and CCR5 might be important in the regulation of the intestinal immune response in this disease, and we speculated that carriers of a defective 32 base pair deletion mutant of CCR5, CCR5Delta32, which results in a non-functional receptor, might be protected from CD. Using polymerase chain reaction (PCR) and PCR restriction fragment length polymorphism (PCR-RFLP) gene frequencies of CCR5Delta32 and of CCR2-641 (replacement of valine-64 by isoleucine in the CCR2 gene) in healthy controls (n=346) and in CD patients (n=235) were determined. In CD patients, subgroup phenotypic analyses were performed according to the Vienna classification. The overall gene frequency of CCR5Delta32 (9.8%) and CCR2-641 (7.6%) in CD patients did not deviate significantly from healthy controls (9.2 and 8.2%, respectively), nor did we observe a significant deviation from the predicted Hardy-Weinberg distribution. No significant differences in the CD phenotype classification for the different CCR5 and CCR2 alleles were observed, except for a trend to disease sparing of the upper gastrointestinal tract (carrier frequency 0 versus 19.6%, Delta=1 9.6%, P=0.079) as well as a more stricturing disease behaviour (23.5 versus 16.2%, Delta=7.3%, P=0.136) in carriers of the mutant CCR5Delta32 allele. These results indicate that the different CCR5 but not CCR2 alleles may influence disease behaviour and thereby contribute to the observed heterogeneity of CD. However, the associations observed are limited and await replication in other datasets. CCR2 and CCR5 polymorphisms are unlikely to be important determinants of overall disease susceptibility.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11377705     DOI: 10.1016/s0165-2478(01)00199-7

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  6 in total

1.  Variants of CCR5, which are permissive for HIV-1 infection, show distinct functional responses to CCL3, CCL4 and CCL5.

Authors:  H-F Dong; K Wigmore; M N Carrington; M Dean; J A Turpin; O M Z Howard
Journal:  Genes Immun       Date:  2005-10       Impact factor: 2.676

Review 2.  The mdr1a-/- mouse model of spontaneous colitis: a relevant and appropriate animal model to study inflammatory bowel disease.

Authors:  Jacque N Wilk; Janine Bilsborough; Joanne L Viney
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

3.  Frequency of CCR5Δ32 allele in healthy Bosniak population.

Authors:  Grażyna Adler; Amina Valjevac; Karolina Skonieczna-Żydecka; Mirela Mackic-Djurovic; Miłosz Parczewski; Anna Urbańska; Nermin Nusret Salkic
Journal:  Bosn J Basic Med Sci       Date:  2014-08-28       Impact factor: 3.363

4.  CCR2-dependent intraepithelial lymphocytes mediate inflammatory gut pathology during Toxoplasma gondii infection.

Authors:  C E Egan; M D Craven; J Leng; M Mack; K W Simpson; E Y Denkers
Journal:  Mucosal Immunol       Date:  2009-09-09       Impact factor: 7.313

5.  Negative association of the chemokine receptor CCR5 d32 polymorphism with systemic inflammatory response, extra-articular symptoms and joint erosion in rheumatoid arthritis.

Authors:  Manuela Rossol; Matthias Pierer; Sybille Arnold; Gernot Keysser; Harald Burkhardt; Christoph Baerwald; Ulf Wagner
Journal:  Arthritis Res Ther       Date:  2009-06-18       Impact factor: 5.156

Review 6.  Chemokine receptors on dendritic cells promote autoimmune reactions.

Authors:  Joost J Oppenheim; De Yang; Arya Biragyn; O M Zack Howard; Paul Plotz
Journal:  Arthritis Res       Date:  2002-05-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.